Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report)'s share price hit a new 52-week low during trading on Wednesday . The stock traded as low as $10.65 and last traded at $10.95, with a volume of 421036 shares trading hands. The stock had previously closed at $11.21.
Wall Street Analyst Weigh In
TYRA has been the topic of a number of research reports. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Tuesday, February 18th. UBS Group assumed coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences currently has a consensus rating of "Buy" and a consensus target price of $30.50.
Get Our Latest Stock Analysis on Tyra Biosciences
Tyra Biosciences Trading Down 1.1 %
The company has a 50-day moving average of $13.90 and a 200-day moving average of $17.53. The company has a market capitalization of $553.60 million, a price-to-earnings ratio of -6.79 and a beta of 1.09.
Insider Buying and Selling
In related news, Director Nina S. Kjellson sold 5,401 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total transaction of $74,317.76. Following the completion of the transaction, the director now directly owns 443,885 shares in the company, valued at $6,107,857.60. The trade was a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 21,998 shares of company stock worth $344,818 in the last 90 days. Insiders own 15.40% of the company's stock.
Institutional Trading of Tyra Biosciences
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Alta Partners Management Company L.P. acquired a new position in shares of Tyra Biosciences in the 4th quarter valued at $56,716,000. Boxer Capital Management LLC purchased a new stake in shares of Tyra Biosciences during the 4th quarter worth about $28,185,000. Janus Henderson Group PLC acquired a new stake in shares of Tyra Biosciences during the 3rd quarter valued at about $24,994,000. Farallon Capital Management LLC purchased a new position in shares of Tyra Biosciences in the 4th quarter valued at about $13,914,000. Finally, Vestal Point Capital LP acquired a new position in Tyra Biosciences in the 4th quarter worth about $13,761,000. 84.14% of the stock is owned by institutional investors and hedge funds.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Recommended Stories
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
